Swaza Inc.

Cover Block

Name	Swaza Inc.
Tagline	Develops nanofluid breathing aid for non-invasive oxygen delivery and CO2 removal in respiratory distress. [Crunchbase]
Headquarters	Mountain View, California
Founded	2022
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Undisclosed

Links

• Website: https://www.swaza.life/
• LinkedIn: https://www.linkedin.com/company/swaza
• JLABS Navigator: https://jnjinnovation.com/JLABSNavigator/company/Swaza_Inc.

Executive Summary

Swaza Inc. is a deep-tech biotechnology startup developing a nanofluid-based platform for non-invasive oxygen delivery. The company's core proposition is a proprietary nanofluid, SWAZA-1, which is reported to deliver oxygen at a concentration 20 times that of lung fluid through fibrotic tissue, targeting both civilian emergency care and military performance enhancement [Perplexity Sonar Pro]. Founded in 2022 by solo founder Niki Santo, the company has maintained a low public profile but secured early validation through membership in the Johnson & Johnson innovation incubator JLABS @ NYC [J&J Innovation].

Its business model is B2B. The company has attracted backing from a small group of investors, including Airstream Venture Partners and APEX Ventures, but has not disclosed any funding round amounts or valuations [Crunchbase].

Data Accuracy: YELLOW -- Core company description and affiliations are consistent across multiple databases, but key technical and financial metrics are unverified.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Undisclosed

How the Company Got Here

Swaza Inc. was founded in 2022 and is headquartered in Mountain View, California [Crunchbase]. The company operates as a deep-tech biotechnology startup, focusing on the development of nanotechnology-based therapeutics [Crunchbase]. Its stated mission is to develop the world's first nanofluid breathing aid to combat acute oxygen loss [LinkedIn].

The company is a member of JLABS @ NYC, the Johnson & Johnson innovation incubator, where it is listed as focusing on pandemic preparedness in communicable diseases and pharmaceuticals [J&J Innovation]. Swaza is also a participant in the Defence Innovation Accelerator for the North Atlantic (DIANA), a NATO-backed program, indicating an active pursuit of dual-use applications for its technology in military performance enhancement [Defence Finance Monitor].

Data Accuracy: YELLOW -- Company details and affiliations confirmed by multiple databases, but key founding and operational details are sparse.

Product and Technology

Swaza's public proposition centers on a single, technically ambitious product: a nanofluid designed to deliver oxygen and remove carbon dioxide non-invasively. The company claims its proprietary platform can deliver oxygen at a concentration 20 times that of lung fluid, even through fibrotic tissue [Perplexity Sonar Pro]. The flagship application is SWAZA-1, characterized as a "nanofluid breathing aid" for use in both civilian emergency care and military performance enhancement [Crunchbase] [Defence Finance Monitor].

Swaza is a member of JLABS @ NYC, Johnson & Johnson's life sciences incubator, which indicates its technology has passed an initial review for scientific merit and commercial potential within the communicable disease and pharmaceutical space [J&J Innovation]. It is also listed as a participant in the Defence Innovation Accelerator for the North Atlantic (DIANA), a NATO-backed program [LinkedIn].

Data Accuracy: YELLOW -- Core product claims are repeated across multiple databases but lack primary technical validation or detailed specification from the company.

Market Research and Opportunity

The opportunity for Swaza is defined by a persistent, global need for novel respiratory support technologies that can function outside of intensive care units and in resource-constrained environments. The company's nanofluid approach targets a critical gap in acute and chronic respiratory care.

Metric	Value
Global Respiratory Care Devices Market (2023)	19.5 $B
Projected CAGR (2023-2030)	8.5 %
Global Oxygen Therapy Market (2024)	21.2 $B
Projected CAGR (2024-2030)	8.7 %

Data Accuracy: YELLOW -- Market sizing figures are from published third-party reports for analogous sectors, not specific to nanofluid therapies.

Competitive Landscape

Swaza’s competitive position is defined by its pursuit of a novel, non-invasive modality for oxygen delivery, a space currently dominated by established mechanical and pharmaceutical incumbents. The company’s nanofluid platform aims to bypass the limitations of existing technologies, but its early stage and lack of clinical validation place it in a distinct, high-risk category.

Swaza’s current defensible edge appears to rest solely on its proprietary technology concept and its affiliation with credible incubators. The company’s membership in JLABS @ NYC provides access to mentorship and a network within Johnson & Johnson’s innovation ecosystem [J&J Innovation]. Its selection for the NATO DIANA accelerator also signals interest from defense stakeholders [Defence Finance Monitor].

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated applications and general market knowledge due to a lack of named competitors in sources.

Opportunity

If Swaza's platform proves viable, the prize is a new, non-invasive therapeutic modality for acute respiratory distress. The company's early validation through its acceptance into the JLABS @ NYC incubator, which focuses on pandemic preparedness and pharmaceuticals, indicates a degree of technical credibility [J&J Innovation].

Scenario	What happens	Catalyst	Why it's plausible
Emergency Care Standard	SWAZA-1 becomes a first-line intervention in ambulances and ERs.	Successful completion of a pivotal clinical trial leading to FDA clearance.	The company's focus on "acute oxygen loss" and membership in JLABS aligns with the regulatory and clinical development process [Crunchbase] [J&J Innovation].
Military Performance Contract	The technology is adopted by a NATO member's defense department.	A development contract or pilot with the Defence Innovation Accelerator for the North Atlantic (DIANA).	The explicit mention of "military performance enhancement" and the DIANA affiliation support this non-dilutive funding path [Perplexity Sonar Pro].

Data Accuracy: YELLOW -- Core opportunity claims are cited from multiple databases but lack primary press or financial disclosure corroboration.

Sources

1. [Crunchbase] Swaza - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/swaza
2. [J&J Innovation] Swaza Inc. - JLABS Navigator | https://jnjinnovation.com/JLABSNavigator/company/Swaza_Inc.
3. [LinkedIn] Swaza | LinkedIn | https://www.linkedin.com/company/swaza
4. [Defence Finance Monitor] Swaza - Strategic-Technological Analysis (Poland) | https://www.defencefinancemonitor.com/p/swaza-strategic-technological-analysis
5. [Grand View Research, 2024] Respiratory Care Devices Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/respiratory-care-devices-market
6. [Fortune Business Insights, 2024] Oxygen Therapy Equipment Market Size, Share & Industry Analysis | https://www.fortunebusinessinsights.com/oxygen-therapy-equipment-market-101770
7. [The Lancet Respiratory Medicine, 2023] COVID-19 and respiratory failure | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00191-6/fulltext
8. [NATO DIANA Charter, 2023] Defence Innovation Accelerator for the North Atlantic | https://www.nato.int/cps/en/natohq/topics_210904.htm